Key result
The HESI Technical Committee Working Groups facilitated the development of platforms for resource sharing and communication among experts to improve cardiac safety evaluation in drug development.
The HESI Cardiac Safety Technical Committee has successfully fostered international collaboration across academia, government, and industry to advance cardiac safety evaluation in drug development.
May enhance cardiac safety via shared platforms; leaves open translation to improved drug development outcomes.
INTRODUCTION: The evaluation of cardiovascular side-effects is a critical element in the development of all new drugs and chemicals. Cardiac safety issues are a major cause of attrition and withdrawal due to adverse drug reactions (ADRs) in pharmaceutical drug development. METHODS: The evolution of the HESI Technical Committee on Cardiac Safety from 2000-2013 is presented as an example of an effective international consortium of academic, government, and industry scientists working to improve cardiac safety. RESULTS AND DISCUSSION: The HESI Technical Committee Working Groups facilitated the development of a variety of platforms for resource sharing and communication among experts that led to innovative strategies for improved drug safety. The positive impacts arising from these Working Groups are described in this article.
No takes yet. Share an insight, caveat, or question.
Pierson et al. (2013) conducted a review in Cardiac safety in drug development. HESI Technical Committee Working Groups was evaluated on Development of platforms for resource sharing and communication. The HESI Technical Committee Working Groups facilitated the development of platforms for resource sharing and communication among experts to improve cardiac safety evaluation in drug development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: